Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
A novel series of potent agonists of the bile acid receptor TGR5 bearing a dihydropyridone scaffold was developed from a high-throughput screen. Starting from a micromolar hit compound, we implemented an extensive structure-activity-relationship (SAR) study with the synthesis and biological evaluation of 83 analogues. The project culminated with the identification of the potent nanomolar TGR5 agonist . We report the GLP-1 secretagogue effect of our lead compound ex vivo in mouse colonoids and in vivo. In addition, to identify specific features favorable for TGR5 activation, we generated and optimized a three-dimensional quantitative SAR model that contributed to our understanding of our activity profile and could guide further development of this dihydropyridone series.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1021/acs.jmedchem.2c01881 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Clostridial-dominated gut microbiota promotes 7α-dehydroxylation of obeticholic acid to lithocholic acid in cholestasis treatment.
Biochem Biophys Res Commun
August 2025
State Key Laboratory of Pharmaceutical Biotechnology, School of Life Sciences, Nanjing University, No.163 Xianlin Avenue, Nanjing 210023, China. Electronic address:
Obeticholic acid (OCA) is a potent farnesoid X receptor (FXR) agonist used in the treatment of liver diseases associated with cholestasis, such as primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC). However, its clinical utility is limited by dose-dependent hepatotoxicity, and the precise mechanism underlying OCA toxicity remains unclear. In this study, we investigated the mechanistic link between cholestasis-induced gut dysbiosis and OCA-associated hepatotoxicity.
View Article and Find Full Text PDFHNF4α contributes to hepatic CAR dysfunction in polymicrobial sepsis.
Front Immunol
September 2025
Center for Inflammation Research, Vlaams Instituut voor Biotechnologie (VIB), Ghent, Belgium.
The constitutive androstane receptor (CAR), encoded by the gene, is a nuclear receptor mainly expressed in the liver, where it regulates (xenobiotic) drug and bile acid metabolism, bilirubin clearance and energy homeostasis. CAR has emerged as a promising therapeutic target for diabetes, fatty liver disease and alcoholic liver disease, but it has barely been investigated in the context of sepsis. Since alterations in drug metabolism have been observed in sepsis patients, who may also exhibit increased serum bilirubin and bile acid levels, we hypothesize that CAR function may be impaired during sepsis.
View Article and Find Full Text PDFBile acids in metabolic dysfunction-associated steatotic liver disease.
World J Hepatol
August 2025
Department of Internal Medicine, Cantonal Hospital Safet Mujić Mostar, Mostar 88000, Bosnia and Herzegovina.
The liver is a central metabolic organ that regulates numerous physiological processes, including glucose and lipid metabolism, detoxification, and the synthesis of essential proteins and bile. Bile acids (BAs), synthesized from cholesterol in hepatocytes, not only facilitate the emulsification and absorption of dietary fats but also act as potent signaling molecules through receptors such as the farnesoid X receptor (FXR) and Takeda G-protein-coupled receptor 5. Metabolic dysfunction-associated steatotic liver disease (MASLD) is a leading cause of chronic liver disease globally, closely linked with obesity, insulin resistance, and other components of metabolic syndrome.
View Article and Find Full Text PDFGut Microbiota-Derived Metabolites Orchestrate Metabolic Reprogramming in Diabetic Cardiomyopathy: Mechanisms and Therapeutic Frontiers.
FASEB J
September 2025
Department of Cardiovascular Medicine, The First Hospital of Jilin University, Changchun, China.
Diabetic cardiomyopathy (DCM) is a major cardiovascular complication of diabetes mellitus, characterized by myocardial structural and functional abnormalities in the absence of overt coronary artery disease or hypertension. A growing body of evidence implicates the gut microbiota and its metabolites as key modulators of systemic metabolic homeostasis, influencing energy metabolism, inflammation, and oxidative stress. The gut microbiota emerges as a novel regulator of cardiac remodeling and metabolic reprogramming in DCM through the gut-heart axis.
View Article and Find Full Text PDFIMM-H007 promotes hepatic cholesterol and triglyceride metabolism by activating AMPK to attenuate hypercholesterolemia.
Acta Pharm Sin B
August 2025
State Key Laboratory for Bioactive Substances and Functions of Natural Medicines, Beijing Key Laboratory of New Drug Mechanisms and Pharmacological Evaluation Study, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China.
Hypercholesterolemia is a significant risk factor for the development of atherosclerosis. 2',3',5'-Tri--acetyl- -(3-hydroxyphenyl) adenosine (IMM-H007), a novel AMPK agonist, has shown protective effects in metabolic diseases. However, its impact on cholesterol and triglyceride metabolism in hypercholesterolemia remains unclear.
View Article and Find Full Text PDF